Tegafur-uracil-induced rapid development of advanced hepatic fibrosis.
World J Gastroenterol
; 23(31): 5823-5828, 2017 Aug 21.
Article
em En
| MEDLINE
| ID: mdl-28883709
ABSTRACT
Tegafur-uracil has been reported to have only minor adverse effects and is associated with liver injury in 1.79% of Japanese patients. The development of tegafur-uracil-induced hepatic fibrosis with portal hypertension is rare. Here, we report a case of a 74-year-old woman with rapidly developing tegafur-uracil-induced hepatic fibrosis. The patient had no history of liver disease and had been treated with tegafur-uracil for 8 mo after breast cancer surgery. The patient was admitted to our hospital for abdominal distension and leg edema associated with liver dysfunction. Computed tomography imaging revealed massive ascites and splenomegaly, and a non-invasive assessment of liver fibrosis indicated advanced fibrosis. The histopathological findings revealed periportal fibrosis and bridging fibrosis with septation. The massive ascites resolved after discontinuing tegafur-uracil. These findings suggest that advanced hepatic fibrosis can develop from a relatively short-term administration of tegafur-uracil and that non-invasive assessment is useful for predicting hepatic fibrosis.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Uracila
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Tegafur
/
Carcinoma Hepatocelular
/
Cirrose Hepática
/
Neoplasias Hepáticas
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article